Wright Investors Service Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 43,246 shares of the biopharmaceutical company’s stock after selling 2,306 shares during the quarter. Gilead Sciences comprises about 1.0% of Wright Investors Service Inc.’s portfolio, making the stock its 29th biggest holding. Wright Investors Service Inc.’s holdings in Gilead Sciences were worth $3,098,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in GILD. Welch Investments LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the third quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management increased its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the sale, the executive vice president now owns 64,613 shares of the company’s stock, valued at approximately $4,772,962.31. The disclosure for this sale can be found here. Insiders sold a total of 430,268 shares of company stock valued at $34,074,395 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
GILD has been the subject of a number of recent research reports. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. Credit Suisse Group reissued a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Maxim Group set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $88.61.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.62 on Wednesday, hitting $81.10. The stock had a trading volume of 6,517,606 shares, compared to its average volume of 8,940,619. The company has a market cap of $106,240.00, a PE ratio of 10.55, a P/E/G ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 EPS. sell-side analysts forecast that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.81%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 27.05%.
ILLEGAL ACTIVITY WARNING: This report was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2018/03/14/wright-investors-service-inc-has-3-10-million-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.